UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000001444
Receipt No. R000001651
Scientific Title Feasibility study of Capecitabine as adjuvant chemotherapy for stage III colon cancer including RS cancer.
Date of disclosure of the study information 2008/10/22
Last modified on 2017/04/30

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Feasibility study of Capecitabine as adjuvant chemotherapy for stage III colon cancer including RS cancer.
Acronym Feasibility study of Capecitabine as adjuvant chemotherapy for stage III colon cancer including RS cancer.
(KSCC0803 study)
Scientific Title Feasibility study of Capecitabine as adjuvant chemotherapy for stage III colon cancer including RS cancer.
Scientific Title:Acronym Feasibility study of Capecitabine as adjuvant chemotherapy for stage III colon cancer including RS cancer.
(KSCC0803 study)
Region
Japan

Condition
Condition stage III colon cancer including RS cancer
Classification by specialty
Gastroenterology Hepato-biliary-pancreatic medicine Hematology and clinical oncology
Surgery in general Gastrointestinal surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 The primary objective of this study is to assess the feasibility of capecitabine as adjuvant chemotherapy in Japan.
Basic objectives2 Safety
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase Phase IV

Assessment
Primary outcomes the rate of completion of treatment as planned
Key secondary outcomes Safety
Cumulative incidence of Hand-foot syndrome and hepatic dysfunction
3-years disease free survival rate
5-years disease free survival rate
3-years overall survival rate
5-years overall survival rate

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Capecitabine is administrated orally as tablets, 2,500 mg/m2 daily for 14 days followed by a 7-days resting period without treatment, as an intermittent therapy in a 3-weeks cycle for 8 treatment cycles.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
80 years-old >=
Gender Male and Female
Key inclusion criteria 1)Histologically confirmed Colorectal adenocarcinoma
2)Histological Stage III Colon,Rectosigmoid
3)Curative resection with D2 or more lymph node dissection
4)Resection of histological curability A was performed
5)age:20-80years old
6)Performance status(ECOG):0or1
7)No prior chemotherapy and radiotherapy
8)Oral intake is possible
9)Sufficient organ functions
10)Chemotherapy will be started within 8 weeks from operation
11)Written informed consent
Key exclusion criteria 1)Pregnant or nursing
2)Medical history of allergy or hypersensitivity reactions to fluoropyrimidines
3)The past of the internal organ transplant
4)Serious coexisting illness
a;severe pulmonary dysfunction
b;ileus or colon dysfunction
c;uncontrolled diabetes mellitus
d;liver cirrhosis
e;uncontrolled hypertension
f;history of myocardial infarction, unstable angina within 6 months prior to the registration
5)Active synchronous or metachronous malignancy other than carcinoma in situ
6)Uncontrollable infectious disease
7)Not suitable for participating in the study for any other reason
Target sample size 92

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Maehara Yoshihiko
Organization Kyushu University
Division name Dpt. of surgery and science
Zip code
Address Maidashi 3-1-1,Higashi-ku,Fukuoka,812-8582
TEL 092-631-2920
Email kscc2@cres-kyushu.or.jp

Public contact
Name of contact person
1st name
Middle name
Last name KSCC
Organization CReS Kyushu
Division name KSCC
Zip code
Address Maidashi 3-1-1,Higashi-ku,Fukuoka,812-8582
TEL 092-631-2920
Homepage URL
Email kscc2@cres-kyushu.or.jp

Sponsor
Institute KSCC
Institute
Department

Funding Source
Organization CReS Kyushu
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 九州大学(福岡県)
国立病院機構九州医療センター(福岡県)
国立病院機構九州がんセンター(福岡県)
公立学校共済組合九州中央病院(福岡県)
済生会福岡総合病院(福岡県)
福岡歯科大学医科歯科総合病院(福岡県)
済生会八幡総合病院(福岡県)
産業医科大学(福岡県)
新日鐵八幡記念病院(福岡県)
国立病院機構福岡東医療センター(福岡県)
社会保険田川病院(福岡県)
社会保険仲原病院(福岡県)
久留米大学(福岡県)
久留米大学医療センター(福岡県)
社会保険久留米第一病院(福岡県)
公立八女総合病院(福岡県)
大牟田市立総合病院(福岡県)
麻生飯塚病院(福岡県)
宗像医師会病院(福岡県)
福岡市民病院(福岡県)
済生会唐津病院(佐賀県)
有田共立病院(佐賀県)
健康保険諫早総合病院(長崎県)
佐世保市立総合病院(長崎県)
白十字会 佐世保中央病院(長崎県)
長崎大学(長崎県)
春回会 井上病院(長崎県)
光晴会病院(長崎県)
国立病院機構長崎医療センター(長崎県)
医理会 柿添病院(長崎県)
済生会熊本病院(熊本県)
熊本赤十字病院(熊本県)
熊本大学(熊本県)
健康保険人吉総合病院(熊本県)
大分県立病院(大分県)
大分赤十字病院(大分県)
国立病院機構大分医療センター(大分県)  
国立病院機構別府医療センター(大分県)
大分大学(大分県)
中津市立中津市民病院(大分県)
大分県済生会日田病院(大分県)
小林市立病院(宮崎県)
宮崎県立延岡病院(宮崎県)
社会保険宮崎江南病院(宮崎県)
宮崎県立日南病院(宮崎県)
国立病院機構南九州病院(鹿児島県)
潤愛会 鮫島病院(鹿児島県)
鹿児島大学(鹿児島県)
鹿児島厚生連病院(鹿児島県)
鹿児島共済会南風病院(鹿児島県)
慈愛会 今村病院(鹿児島県)
県民健康プラザ鹿屋医療センター(鹿児島県)
鹿児島県立薩南病院(鹿児島県)
浦添総合病院(沖縄県)
中頭病院(沖縄県)
ハートライフ病院(沖縄県)
琉球大学(沖縄県)
北部地区医師会病院(沖縄県)
広島赤十字・原爆病院(広島県)
松山赤十字病院(愛媛県)
防府消化器病センター 防府胃腸病院(山口県)

Other administrative information
Date of disclosure of the study information
2008 Year 10 Month 22 Day

Related information
URL releasing protocol
Publication of results Partially published

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2008 Year 07 Month 16 Day
Date of IRB
Anticipated trial start date
2008 Year 07 Month 16 Day
Last follow-up date
2014 Year 09 Month 01 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2008 Year 10 Month 21 Day
Last modified on
2017 Year 04 Month 30 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001651

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.